Figure 2.

Inhibition of tumor promotion by retinoid SR11302, but not by SR11235, in AP-1-luciferase transgenic mice. Transgenic mice that expressed a 2X TRE luciferase reporter gene were grouped and initiated with DMBA as well as treated twice a week with TPA with or without different tumor prevention drugs such as FA, RA, and SR11302 or SR11235, as described. SR11302 and SR11235 are new synthetic retinoids with selective inhibiting AP-1 activation and activating RARE activity, respectively. The results are shown as the average number of papillomas per mouse with the mean ± SE at week 18 after tumor promotion.